Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AIMNYSE:CHRONASDAQ:CURNASDAQ:FRTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMAIM ImmunoTech$0.09-22.3%$0.10$0.06▼$0.47$6.61M0.76570,559 shs2.31 million shsCHROChromocell Therapeutics$0.95-1.6%$1.27$0.45▼$3.80$6.27M4.59433,535 shs16,357 shsCURNeuralstem$0.77-5.5%$1.06$1.10▼$13.78$1.61M1.81236,278 shs132,090 shsFRTXFresh Tracks Therapeutics$0.94-0.5%$0.94$0.03▼$1.03$5.59M0.542,709 shs2,402 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMAIM ImmunoTech0.00%0.00%0.00%-28.54%-73.89%CHROChromocell Therapeutics-0.52%-2.53%-28.52%-52.93%-29.04%CURNeuralstem+0.35%+9.89%+12.47%-7.14%-83.51%FRTXFresh Tracks Therapeutics0.00%0.00%0.00%-0.53%+8.71%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAIMAIM ImmunoTech1.6339 of 5 stars3.50.00.00.00.61.70.6CHROChromocell TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACURNeuralstemN/AN/AN/AN/AN/AN/AN/AN/AFRTXFresh Tracks TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMAIM ImmunoTech 3.00Buy$2.752,908.75% UpsideCHROChromocell Therapeutics 3.00BuyN/AN/ACURNeuralstem 0.00N/AN/AN/AFRTXFresh Tracks Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMAIM ImmunoTech$170K38.87N/AN/A$0.20 per share0.46CHROChromocell TherapeuticsN/AN/AN/AN/A($1.65) per shareN/ACURNeuralstem$260K6.18N/AN/A$6.64 per share0.12FRTXFresh Tracks Therapeutics$10.06M0.56N/AN/A$1.66 per share0.56Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMAIM ImmunoTech-$28.96M-$0.31N/AN/AN/A-12,594.21%-421.73%-147.54%N/ACHROChromocell Therapeutics-$7.38M-$1.24N/A∞N/AN/AN/A-453.90%N/ACURNeuralstem-$4.93MN/A0.00∞N/A-39,417.64%-170.51%-110.16%N/AFRTXFresh Tracks Therapeutics-$5.69M-$1.41N/A∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIMAIM ImmunoTechN/AN/AN/AN/AN/ACHROChromocell TherapeuticsN/AN/AN/AN/AN/ACURNeuralstemN/AN/AN/AN/AN/AFRTXFresh Tracks TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMAIM ImmunoTech0.050.750.75CHROChromocell TherapeuticsN/A0.600.60CURNeuralstemN/A2.532.53FRTXFresh Tracks TherapeuticsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMAIM ImmunoTech12.02%CHROChromocell Therapeutics77.96%CURNeuralstem38.30%FRTXFresh Tracks Therapeutics25.04%Insider OwnershipCompanyInsider OwnershipAIMAIM ImmunoTech0.02%CHROChromocell Therapeutics16.40%CURNeuralstem5.38%FRTXFresh Tracks Therapeutics0.23%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIMAIM ImmunoTech2072.29 million68.74 millionNot OptionableCHROChromocell Therapeutics46.60 million5.04 millionN/ACURNeuralstem62.10 millionN/ANot OptionableFRTXFresh Tracks Therapeutics205.97 million5.96 millionNot OptionableCUR, AIM, CHRO, and FRTX HeadlinesRecent News About These CompaniesFresh Tracks Therapeutics Announces Dissolution, Initial Cash Distribution and Termination of Trading on the OTC Pink MarketFebruary 26, 2025 | finance.yahoo.comFresh Tracks to cease stock trading as drug company dissolvesFebruary 26, 2025 | bizwest.comFresh Tracks Therapeutics Announces Dissolution, Initial Cash Distribution and Termination of Trading on the OTC Pink MarketFebruary 25, 2025 | prnewswire.comFresh Tracks Therapeutics Announces Appointment of Custodian and Planned DistributionJanuary 27, 2025 | finance.yahoo.comFresh Tracks Therapeutics Announces Hearing Date and Notice of Proposed Consent Judgement Regarding Dissolution of CompanyDecember 6, 2024 | prnewswire.comFresh Tracks Therapeutics (OTC:FRTX) Stock, Short Interest ReportOctober 18, 2024 | benzinga.comFresh Tracks Therapeutics (OTC:FRTX) Stock Quotes, Forecast and News SummaryOctober 18, 2024 | benzinga.comFresh Tracks Therapeutics Inc (FRTX)August 31, 2024 | uk.investing.comAjofé Drops “One Time,” a Timeless Track with a Fresh BeatAugust 30, 2024 | thisdaylive.comFresh Tracks Therapeutics Announces Delaware Petition Filed Seeking Appointment of Custodian for Eventual Dissolution of CompanyJune 17, 2024 | globenewswire.comFresh Tracks Therapeutics Inc. (FRTX) Institutional HoldingsMay 25, 2024 | nasdaq.comExploration capital buys fresh tracks therapeutics shares worth over $19kApril 25, 2024 | investing.comExploration capital purchases Fresh Tracks Therapeutics stock worth $2,805April 13, 2024 | investing.comFresh Tracks Therapeutics, Inc.: Fresh Tracks Therapeutics Urges Stockholders to Vote at the Upcoming Special Meeting on February 15thFebruary 16, 2024 | finanznachrichten.deFresh Tracks Therapeutics Urges Stockholders to Vote at the Upcoming Special Meeting on February 15thFebruary 14, 2024 | finance.yahoo.comFresh Tracks Therapeutics Urges Stockholders to Vote at the Upcoming Special Meeting on February 15thFebruary 14, 2024 | globenewswire.comFresh Tracks Therapeutics IncJanuary 3, 2024 | morningstar.comFresh Tracks leaders doubt they have support for liquidationDecember 28, 2023 | bizwest.comFresh Tracks Therapeutics Announces Plan to Hold New Special Meeting of Stockholders on February 15thDecember 27, 2023 | finance.yahoo.comFresh Tracks Therapeutics, Inc.: Fresh Tracks Therapeutics Announces Listing on OTC Pink MarketDecember 20, 2023 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesThese Are the Only 6 Stock Stocks in NVIDIA's 13F PortfolioBy Leo Miller | May 22, 2025View These Are the Only 6 Stock Stocks in NVIDIA's 13F Portfolio3 Mid-Cap Stocks Turning Heads in AI, Automation, & CybersecurityBy Nathan Reiff | May 16, 2025View 3 Mid-Cap Stocks Turning Heads in AI, Automation, & CybersecurityAmazon: Why The Great Comeback Rally Could Be About to BeginBy Sam Quirke | May 5, 2025View Amazon: Why The Great Comeback Rally Could Be About to BeginTaiwan Semiconductor Has a New Reason to Rally on Chip CurbsBy Gabriel Osorio-Mazilli | May 9, 2025View Taiwan Semiconductor Has a New Reason to Rally on Chip CurbsGlobalFoundries Stock Hits Bottom: Is a Rebound Coming?By Thomas Hughes | May 10, 2025View GlobalFoundries Stock Hits Bottom: Is a Rebound Coming?CUR, AIM, CHRO, and FRTX Company DescriptionsAIM ImmunoTech NYSE:AIM$0.09 -0.03 (-22.34%) As of 04/4/2025 This is a fair market value price provided by Polygon.io. Learn more.AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.Chromocell Therapeutics NYSE:CHRO$0.95 -0.02 (-1.55%) Closing price 04:00 PM EasternExtended Trading$0.94 -0.01 (-0.63%) As of 04:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.Neuralstem NASDAQ:CURNeuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its lead product candidate is NSI-189, a chemical entity, which has been completed Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical study for the treatment-refractory depression, Angelman Syndrome, Alzheimer's disease, ischemic stroke, diabetic neuropathy, irradiation-induced cognitive deficit, and long-term potentiation enhancement. The company also develops NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease; Phase II clinical trial for the treatment of chronic ischemic stroke; and Phase I clinical trials for the treatment of chronic spinal cord injury, as well as is in preclinical study for the traumatic brain injury. In addition, it develops NSI-532, which is in preclinical study for treatment of Alzheimer's disease; and NSI-777 that is in preclinical study for treatment of human demyelinating diseases. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.Fresh Tracks Therapeutics NASDAQ:FRTX$0.94 -0.01 (-0.53%) As of 02/28/2025Fresh Tracks Therapeutics, Inc. does not have significant operations. Previously, the company was engaged in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hormel Stock Near Lows, But Tariff Relief Could Boost Outlook Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Intel's Loss Is Broadcom's Gain as AVGO Dominates Networking Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
